论文信息 - A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). - 字舞流文

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

H. Groen | M. Socinski | C. Gridelli | L. Tye | P. Baas | E. Juhász | C. Butts | R. Chao | J. Williams | F. Grossi | P. Selaru | G. Blumenschein | T. Usari | F. Gao | E. Chmielowska | C. Harmon